TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02079922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06678552
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
Study: NCT00971685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone
Description: RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
Study: NCT01814995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition/Physical Activity Intervention
Description: Please see Arm description.
Study: NCT04562298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-M23 cells
Description: Prior to infusion of LCAR-M23, subjects will receive a premedication regimen (intravenous infusion of cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2 once daily for 3 days; fludarabine dose reduction to 25 mg/m2 and cyclophosphamide to 250 mg/m2 are allowed if the subject' s creatinine clearance is 50-70 mL/min/1.73 m2). A single dose, single Infusion of LCAR-M23 is scheduled 5 to 7 days after the initiation of the premedication regimen.
Study: NCT03121469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Papillon +TM
Description: Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
Study: NCT04153201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200 mg daily for patients weighing \< 60 kg, hydroxychloroquine 400 mg daily for patients weighing \>= 60 kg
Study: NCT02272881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical reconstruction
Description: Patients randomized to surgical flap closure will undergo reconstructive plastic surgery to close an intended pressure ulcer at the earliest date after selection. Our group's co-investigator and staff plastic and reconstructive surgeon will decide on the optimal technical repair. Given the lack of retrospective evidence to support a superior surgical repair (myocutaneous, fasciocutaneous, local flap arrangement versus free microvascular tissue transfer) we will defer to our physician staff preference on a per patient basis. The time from enrollment to surgical intervention will be tracked, and no patient will be dropped from the study should this time exceed the two-week ideal.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: wound management
Description: Patients selected to the supportive wound care arm will be managed by the Center for Wound Care at Cottage Health System, a certified wound care center. They will receive standard of care conservative wound care including: debridement, dressing changes, wound checks, physical therapy, occupational therapy, antibiotic treatment, nutritional support and close follow-up over the study period.
Study: NCT01866410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02488902

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 25mg
Description: Tafenoquine 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 50mg
Description: Tafenoquine 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 100 mg
Description: Tafenoquine 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg
Description: Tafenoquine 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine 250 mg
Description: Mefloquine 250 mg
Study: NCT01931137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Dose level of 8100 nmol will be orally administered as one tablet per dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Dose level of 8100 nmol will be orally administered as one tablet per dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Dose level of 8100 nmol will be orally administered as one tablet per dose.
Study: NCT04887974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: canine retraction
Description: Canine retraction using elastomeric chains activated every 4 weeks, using power arms to direct force through the center of resistance and TADs for direct anchorage.
Study: NCT01309828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Fixed-dose combination tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil and hydrochlorothiazide
Description: Fixed-dose combination tablets.
Study: NCT03360656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transnasal Thermal Regulating Device
Description: Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 8 to 24 hours
Study: NCT00738920

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Administered Cognitive Behavior Therapy
Description: This 4 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist Administered Cognitive Behavior Therapy
Description: This 10 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Education and Supportive Therapy
Description: This 4 session treatment aims at controlling symptoms through support and the provision of information about IBS symptoms, how it is diagnosed, its causes, and treatment options and a collaborative, relationship between the patient and doctor
Study: NCT02323139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine and LDE255
Description: Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)
Study: NCT01625286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363 when combined with weekly paclitaxel.
Description: AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363 when combined with weekly paclitaxel.
Description: AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD5363when combined with weekly paclitaxel.
Description: Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A placebo in combination with weekly paclitaxel.
Description: Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
Study: NCT02252497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator : Tranexamic Acid (Exacyl)
Description: * 1g Exacyl Intra Venous, just before surgery~* Then infusion of 1g of Exacyl over eight hours .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator : physiologic serum
Description: * 1g Intra Venous just before surgery~* Then infusion of 1g of physiologic serum over eight hours
Study: NCT03881579

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: nurse-led supportive care assessment
Description: Trained project nurses will conduct systematic assessment and provide coaching to patients in the experimental arm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led supportive care assessment
Description: Trained project nurses will conduct systematic assessment and provide coaching to patients in the experimental arm
Study: NCT02100527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: 200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
Study: NCT00931021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline (Chantix)
Description: 2 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: 21 mg
Study: NCT05867602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: intravenous human albumin at a dose of (1g/kg), with a minimum dose of 50g and a maximum dose of 100g
Study: NCT03584334

Intervention type: RADIATION
Group type: OTHER
Intervention: 18FDG PET
Description: Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
Study: NCT00651833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the third stage only if 7/31 (23%) or more patients have achieved a confirmed response (CR or PR) in stages 1 and 2 combined.
Study: NCT04257318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrating Relaxation Tool
Description: Use of a Vibrating Relaxation Tool in case of pain during pregnancy
Study: NCT03509935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Ultrasound Group
Description: Protocol:~* US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions (figure 1)~* US inferior vena cava, collaborative index or distensibility according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~* Cardiac US: subjective evaluation of contractility in normal, discreetly reduced or severely reduced.
Study: NCT01271335

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase
Description: Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
Study: NCT00811083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMSA - dimercaptosuccinic acid
Description: dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
Study: NCT00256100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux Sodium
Description: The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux Sodium
Description: The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
Study: NCT01384864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proflavine
Description: 2-6 ml of 0.01% proflavine
Study: NCT03948737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Tocopherol
Description: all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.
Study: NCT03948737

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpha-Tocopherol
Description: all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Study: NCT02268331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Surveillance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Surveillance
Study: NCT00299273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low calorie high fat/protein diet
Description: 6 weeks of caloric restriction (50%) on a high fat/protein diet
Study: NCT03503474

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention, this is observational only

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention, this is observational only
Study: NCT00529802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: take 2 tablets of RAD001 once a day by mouth (10 mg per day)
Study: NCT00827359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Tablet form taken orally once a day
Study: NCT03251209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical practice
Description: Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical practice
Description: Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical practice
Description: Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice
Description: Mental practice: think about the tasks watched in the videotherapy (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles) for 5 minutes / task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice
Description: Mental practice: think about the tasks watched in the videotherapy (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles) for 5 minutes / task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videotherapy
Description: Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videotherapy
Description: Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videotherapy
Description: Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)
Study: NCT02409537

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: red wine
Description: the individuals were given red wine to consume for 1 month then a wash out period of 1 month

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: red wine
Description: the individuals were given red wine to consume for 1 month then a wash out period of 1 month
Study: NCT04473404

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius DB-B5 - 2 billion CFU/day
Description: The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 1 billion CFU/sachet) dissolved in water twice daily for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius DB-B5 - 10 billion CFU/day
Description: The participants (n=15) will consume sachets containing Streptococcus salivarius DB-B5 (at 5 billion CFU/sachet) dissolved in water twice daily for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants (n=15) will consume sachets containing a placebo (probiotic carrier) twice daily for 4 weeks.
Study: NCT02817789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor alone
Description: 180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination lysine acetylsalicylate - clopidogrel
Description: 75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
Study: NCT02409537

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: the individuals were given resveratrol for 1 month and then 1 month wash out period
Study: NCT02438449

Intervention type: PROCEDURE
Intervention: Breast Reconstruction Surgery
Description: AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy

Intervention type: PROCEDURE
Intervention: Breast Reconstruction Surgery
Description: AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
Study: NCT02801045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: art therapy
Description: Patient's creativity is stimulated by visual arts materials and various art therapy techniques including punctual use of music, poetry and body expression. The intervention, based on the investigators previous experience, is founded on:~* humanistic phenomenological focus~* transpersonal therapeutic bound~* transdisciplinarity in the artistic approach~* integrative-relational specialized counseling of the grief, loss and trauma aspects.
Study: NCT04045392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.
Study: NCT03057548

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryo or RF Ablation only of Pulmonary Veins
Description: Artic Front Advance Cardiac Cryoabltion System used to ablate the Pulmonary Veins~OR~FDA Approved RF Ablation Catheter used to ablate the Pulmonary Veins.~Ablation of the Pulmonary Veins alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryo or RF Ablation of Pulmonary Veins plus Ablation of the PLAW
Description: Cryoablation of the Pulmonary Veins plus RF Ablation of the PLAW~OR~RF Ablation of the Pulmonary Veins plus RF Ablation of the PLAW~Ablation of the Pulmonary Veins plus RF ablation of the Posterior Left Atrial Wall (PLAW)
Study: NCT03727204

Intervention type: PROCEDURE
Intervention: On-pump cardiac surgery
Description: All participants will undergo on-pump cardiac surgery

Intervention type: PROCEDURE
Intervention: On-pump cardiac surgery
Description: All participants will undergo on-pump cardiac surgery
Study: NCT03424876

Intervention type: DRUG
Intervention: Imatinib 400mg
Description: exposure 400 mg/day or 600mg/day,
Study: NCT02409537

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: the individuals were given resveratrol for 1 month and then 1 month wash out period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: the individuals were given placebo for 1 month
Study: NCT03424876

Intervention type: DRUG
Intervention: Sunitinib 37.5Mg Oral Capsule
Description: exposure 37.5 mg/day, continuous taking, or 50 mg/day (4/2)
Study: NCT02409537

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: the individuals were given placebo for 1 month
Study: NCT03661294

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: GE Healthcare Metabolic Oxygenator
Study: NCT02688101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DpC
Description: iron chelator
Study: NCT03612401

Intervention type: DRUG
Group type: OTHER
Intervention: Mirabegron
Description: Beta-3 adenoreceptor agonist
Study: NCT00886782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cdc7-inhibitor
Description: Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months
Study: NCT01260246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: pill, 100mg/daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo match for 6 months
Study: NCT00107419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression